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ATP is essential for cellular function and is usually produced through oxidative phosphorylation. How-
ever, mitochondrial dysfunction is now being recognized as an important contributing factor in the
development cardiovascular diseases, such as pulmonary hypertension (PH). In PH there is a metabolic
change from oxidative phosphorylation to mainly glycolysis for energy production. However, the me-
chanisms underlying this glycolytic switch are only poorly understood. In particular the role of the re-
spiratory Complexes in the mitochondrial dysfunction associated with PH is unresolved and was the
focus of our investigations. We report that smooth muscle cells isolated from the pulmonary vessels of
rats with PH (PH-PASMC), induced by a single injection of monocrotaline, have attenuated mitochondrial
function and enhanced glycolysis. Further, utilizing a novel live cell assay, we were able to demonstrate
that the mitochondrial dysfunction in PH-PASMC correlates with deficiencies in the activities of Com-
plexes I–III. Further, we observed that there was an increase in mitochondrial reactive oxygen species
generation and mitochondrial membrane potential in the PASMC isolated from rats with PH. We further
found that the defect in Complex I activity was due to a loss of Complex I assembly, although the as-
sembly of Complexes II and III were both maintained. Thus, we conclude that loss of Complex I assembly
may be involved in the switch of energy metabolism in smooth muscle cells to glycolysis and that
maintaining Complex I activity may be a potential therapeutic target for the treatment of PH.
& 2015 Published by Elsevier B.V.1. Introduction
Mitochondria convert nutrients into ATP using a highly effec-
tive energy-transformation process. ATP production by mi-
tochondria involves the oxidation of glucose that generates 36 mol
of ATP per 1 mol of glucose. The cytosolic production of energy
called – glycolysis is far less efficient and produces only two ATP
molecules per glucose. However, glycolysis is still required for
mitochondrial ATP production, because it supplies the pyruvate
molecules necessary for mitochondrial activity. Therefore, under
physiologic conditions, cells use both mitochondrial oxidative
phosphorylation and glycolysis for energy generation. However, itl and Regenerative Medicine,
ucson, AZ 85724, USA.
a.edu (R. Rafikov),is becoming increasingly evident that under certain disease con-
ditions there is damage to the mitochondrion that limits its ability
to generate ATP via oxidative phosphorylation. Under these con-
ditions of mitochondrial dysfunction, cells switch from oxidative
phosphorylation to an aerobic glycolytic production of ATP, the so-
called Warburg effect.
The mitochondrial electron transfer chain consists of five dis-
tinct Complexes. Electrons enter the respiratory chain at Complex I
from NADH, or Complex II as it catabolizes succinate. Both Com-
plexes transfer electrons to Coenzyme Q, which then shuttles the
electrons to Complex III. Cytochrome c further transfers electron to
Complex IV, which combines them with oxygen to produce water.
All four Complexes use energy from the electron flow to pump
protons from the mitochondrial matrix into the intermembrane
space. The proton gradient generated in this process adds about
40% of its energy to the synthesis of ATP via Complex V. Thus,
together, Complexes I–IV, CoQ and cytochrome c form the electron
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mitochondrial respiratory chain. Under physiologic conditions,
vascular smooth muscle cells (SMC) exist in a differentiated, con-
tractile state. However, SMC are susceptible to phenotype mod-
ulation [1]. During this process, SMC undergo a transition from
their normal contractile, differentiated phenotype to one that ex-
hibits a synthetic proliferative, dedifferentiated phenotype [2,3].
This phenotype modulation contributes to the pathogenesis of a
number of cardiovascular disorders, including pulmonary hy-
pertension (PH) [4,5]. Recent work both from our lab, and others,
has identified impaired mitochondrial function in PASMC [6,7] and
PAEC [8–11] in PH that results in a survival advantage [11]. This
survival advantage is thought to be due to the cells switching from
oxidative phosphorylation to glycolysis, in order to generate cel-
lular ATP [12]. However, the underlying mechanisms responsible
for this glycolytic switch are still unresolved. In particular, it is
unclear where, within the mitochondrial respiratory chain, do the
derangements lie.
Thus, the focus of this study was to determine if there are
defects in the activities of the electron transport system in PASMC
isolated from rats with PH. Our data indicate the mitochondrial
dysfunction in PASMC isolated from rats with PH correlates with
deficiencies in the activities of Complexes I, II and III. We also
identified increases in mitochondrial reactive oxygen species
generation and mitochondrial membrane potential. The defect in
Complex I activity correlates with a loss in its assembly, although
the assembly of Complexes II and III are both maintained.2. Methods
2.1. Animals
A total of 110 male Sprague Dawley rats (SD; 220–270 g) were
used in this study (n¼5–10 per group). Animals were housed in
the Georgia Regents University animal care facility for at least
1 week before being used in the experiments. Animals were kept
in a 12-h light/dark cycle at an ambient temperature of 22 °C and
received standard rodent food and water ad libitum. All experi-
mental procedures were approved by the Institutional Animal Care
and Use Committee at Georgia Regents University. Monocrotaline
rats received either a single injection of vehicle (Control group) or
monocrotaline (60 mg/kg, MCT group) to induce pulmonary hy-
pertension (PH). All animals were sacrificed 28 days after injection.
2.2. Smooth muscle cells (SMC) isolation
Rats were sacrificed, and the heart and lung are removed in one
piece. The lobes of the lung were then separated into whole pieces
in preparation for removal of the main pulmonary artery. The main
pulmonary artery was then removed, opened and gently swabbed
to remove the endothelial cells. The denuded vessels were then
cut into small pieces and added to an enzyme solution consisting
of 37 mg of collagenase type 2 (Worthington) and 125 mg of BSA
in 10 ml of dissociation buffer. Vessels were then incubated for
30 min at 37 °C. After enzyme digestion, the samples were re-
moved and vigorously vortexed. Cells were then precipitated by
centrifugation at 2000g for 10 min. The resulting pellet was then
resuspended in 3 ml of 10% FBS DMEM medium containing an
antibiotic/antifungal solution. Cells were confirmed as SMC by
staining with smooth muscle cell actin. Cells were plated for
7 days then reseeded for Seahorse XF experiments or harvested for
mitochondrial isolation.2.3. Mitochondrial bioenergetics
The XF24 Analyzer (Seahorse Biosciences, North Billerica, MA,
USA) was used to measure changes in mitochondrial bioenergetics
by measuring the oxygen consumption rate (OCR). PASMC were
plated on XF24 culture microplates. The optimum number of
PASMC/well was determined to be 40,000/0.32 cm2. Dulbecco's
modified Eagle's medium (DMEM, pH 7.4) supplemented with
5 mM glucose and 2 mM sodium pyruvate was then added. The
plates were then incubated in a CO2-free XF prep station at 37 °C
for 40 min to allow temperature and pH calibration. We then se-
quentially injected Oligomycin (1 mm final concentration); an ATP
synthase inhibitor, which decreases OCR levels, followed by FCCP
(carbonyl cyanide 4- (trifluoromethoxy) phenylhydrazone, 1 mm
final concentration); an electron transport chain accelerator which
causes maximal respiration and finally Rotenoneþantimycin A
(1 mm final concentration of each) which are mitochondrial Com-
plex 1 and III inhibitors, respectively. Subsequently, the mi-
tochondrial respiratory parameters were calculated from the OCR
values. All the OCR values were expressed in pmoles/min of oxy-
gen consumed. All the drugs were used from the XF Cell Mito
Stress Test Kit (# 101706-100; Seahorse Biosciences). Reserve ca-
pacity was calculated as the difference in between basal OCR and
that obtained in the presence of FCCP. Maximal respiratory capa-
city was determined as the difference in OCR between Roteno-
neþAntimycin A and FCCP.
2.4. Analysis of cellular glycolysis
To estimate changes in cellular glycolytic rates we measured
changes in the extracellular acidification rate (ECAR). PASMC were
glucose-starved in XF assay medium in a CO2-free XF prep station
at 37 °C for 40 min and then sequentially injected with glucose
(2 mg/ml), oligomycin (1 mM) and 2-deoxy-D-glucose (100 mM).
Differences in basal-, maximal- and spare glycolytic capacity were
then determined and the data represented as mpH/min. Spare
glycolytic capacity was determined as the difference in ECAR be-
tween basal ECAR and that obtained in the presence of oligomycin.
2.5. Respiratory chain complex functional analysis in permeabilized
pulmonary arterial smooth muscle cells
Cells were seeded in an XF24 cell culture microplate at 20,000
cells per well two days before the initiation of the experiment. On
the days of the experiment, cells were washed with 1 MAS
buffer (Mannitol 220 mM, Sucrose 70 mM, KH2PO4 10 mM, MgCl2
5 mM, HEPES 2 mM, EGTA 1 mM, Fatty Acid Free (FAF) BSA 0.2%
(w/v)). A Pyruvate/Malate/ADP (10 mM/1 mM/4 mM respectively)
mixture was added to the MAS buffer to form the assay medium.
Prior to starting the assay, mitochondrial Complex substrates and
inhibitors, in 1 MAS buffer, were added to the injection ports of
the cartridge: Port 1: Complex I inhibitor – rotenone (2 mM), Port
2: Complex II substrate – succinate (10 mM) or the Complex III
substrate-tetramethyl-hydroquinone (0.5 mM), Port 3: Complex V
inhibitor – oligomycin (1 mM). Cells were then treated with plasma
membrane permeabilizer (1 nM XF PMP (Seahorse Biosciences),
final volume of 0.5 ml per well) mixed with assay medium to in-
itiate the experiment and immediately transfered to the XF24
analyzer. Initial readings were used to determine the basal OCR of
respiring mitochondria (Stage 1). To determine the Complex I
component of the OCR, the Complex I inhibitor, rotenone (2 mM)
was injected (Stage 2). The difference in OCR between Stage 1 and
2 was attributed to the respiratory activity of Complex I. The
Complex II substrate, succinate, was then injected to activate
electron flow through Complex II, and bypass the need for Com-
plex I (Stage 3). The difference in OCR between Stage 2 and 3 was
Fig. 1. Mitochondrial respiration is attenuated in pulmonary arterial smooth muscle cells isolated from rats with pulmonary hypertension. The Seahorse XF24 analyzer was
used to take measurements in PASMC (40,000/0.32 cm2) isolated from control (red) and PH (blue) rats. Oligomycin (1 mM), FCCP (1 mM), and Rotenone and Antimycin A
(1 mM each) were added at the indicated points (A). Basal mitochondrial respiration (B) is unchanged between control and PH-PASMC as estimated by measuring the rate of
oxygen consumption rate (OCR, pmols/min). Both the maximal respiratory capacity (C) and the reserve respiratory capacity (D) are significantly attenuated in PH-PASMC.
Values are means7SEM. *(po0.05 vs. Control PH-PASMC, N¼10 measurements from 3 independent SMC isolations). (For interpretation of the references to color in this
figure legend,the reader is referred to the web version of this article.)
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set of studies, Complex III activity was stimulated by the injection
of tetramethyl-hydroquinone (0.5 mM) after the injection of ro-
tenone (Stage 3). Again the difference in OCR between Stage 2 and
3 was attributed to the respiratory activity of Complex III. In both
studies, as a last challenge, oligomycin was injected to attenuate
ATP synthase activity (Stage 4). This served as a control to ensure
that mitochondrial respiration was being measured. In the assay
we utilized mix/wait/measure times of 0.5 min/0.5 min/2 minwith
no equilibration step and took 2 measurements per step.
2.6. Determination of mitochondrial ROS levels
MitoSOX™ Red mitochondrial superoxide indicator (Molecular
Probes, Grand Island, NY) a fluorogenic dye for selective detection
of superoxide in the mitochondria of live cells was used. Briefly,
cells were washed with fresh media, and then incubated in media
containing MitoSOX Red (2 mM), for 30 min at 37 °C in dark con-
ditions then subjected to fluorescence microscopy at an excitation
of 510 nm and an emission at 580 nm. An Olympus IX51 micro-
scope equipped with a CCD camera (Hamamatsu Photonics) was
used for acquisition of fluorescent images. The average fluorescent
intensities (to correct for differences in cell number) were quan-
tified using ImagePro Plus version 5.0 imaging software (Media
Cybernetics).
2.7. Analysis of mitochondrial membrane potential
Mitochondrial membrane potential was determined using tet-
ramethylrhodamine methyl ester perchlorate, TMRM (Molecular
Probes, Eugene, OR). Briefly, cells were washed with fresh media,
and incubated in media containing TMRM (50 nM), for 30 min at
37 °C in dark conditions then subjected to fluorescence micro-
scopy at an excitation of 510 nm and an emission at 580 nm. AnOlympus IX51 microscope equipped with a CCD camera (Hama-
matsu Photonics) was used for acquisition of fluorescent images.
The average fluorescent intensities (to correct for differences in
cell number) were quantified using ImagePro Plus version
5.0 imaging software (Media Cybernetics).
2.8. Mitochondrial isolation and analysis of electron chain complexes
Mitochondria from PASMC were isolated using the Pierce Mi-
tochondria isolation kit for cultured cells (Pierce, Rockford, IL) as
previously described [13]. Pelleted mitochondria samples were
solubilized in cold 1X NativePAGE™ Sample Buffer (Life technol-
ogies) containing 1% n-dodecyl-β-D-maltoside (DDM) and 1% Di-
gitonin and mixed by pipetting up and down. Samples were in-
cubated on ice for 15 min, and then centrifuged at 20,000 g for
30 min at 4 °C. Samples were loaded in wells filled with 1X Nati-
vePAGE™ Dark Blue Cathode Buffer prior to filling the cathode
chamber to better visualize the sample wells. The upper Cathode
Buffer Chamber was filled with 200 mL 1 NativePAGE™ Dark
Blue Cathode Buffer, and the Lower Anode Buffer Chamber filled
with 550 mL NativePAGE™ Anode Buffer. Electrophoresis was run
for 120 min at 150 V.
2.9. Statistical analysis
Statistical analysis was performed using GraphPad Prism ver-
sion 4.01 for Windows (GraphPad Software). The mean7SEM
were calculated for all samples and significance was determined
by the unpaired t-test. A value of po0.05 was considered
significant.
3. Results
3.1. Disrupted bioenergetics in pulmonary arterial smooth muscle
Fig. 2. Glycolysis is increased in pulmonary arterial smooth muscle cells isolated from rats with pulmonary hypertension. The Seahorse XF24 analyzer was used to take
extracellular acidification rate (ECAR) measurements in PASMC (20,000/0.32 cm2) isolated from control (red, N¼10) and PH (blue, N¼10) rats. D-glucose (2 mg/ml), oli-
gomycin (1 mM) and 2-deoxy-D-glucose (100 mM) were added at the indicated points (A). There is no difference in the glycolytic rate between control and PH-PASMC in the
absence of substrate (B). However, the addition of D-glucose caused a significant increase in ECAR in PH- compared to Control-PASMC (C). The addition of oligomycin
increased ECAR significantly more in PH- compared to control-PASMC (D). Values are means7SEM. *(po0.05 vs. Control PH-PASMC, N¼10 measurements from 3 in-
dependent SMC isolations). (For interpretation of the references to color in this figure legend,the reader is referred to the web version of this article.)
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In PASMC isolated from control and MCT-treated rats, oxygen
consumption rates were monitored (Fig. 1A). Our data identified a
similar level of basal respiration between control- and PH-PASMC
(Fig. 1B). Interestingly, the decrease in OCR in control PASMC ex-
posed to oligomycin was significantly greater than that in the PH
PASMC. This may reflect additional non-mitochondrial oxygen
consumption in the PH cells. In addition, both spare and maximal
respiratory capacities were significantly reduced in PASMC iso-
lated from rats with PH (Fig. 1C and D).3.2. Increased glycolysis in pulmonary arterial smooth muscle cells
isolated from rats with pulmonary hypertension
In PASMC isolated from contro–l and MCT-treated rats, acid-
ification rates were monitored to estimate glycolysis. Our data
identified a similar level of basal acidification between control-
and PH-PASMC (Fig. 2A). After challenge with glucose the acid-
ification rate was significantly higher in PH-PASMC (Fig. 2B). Our
data also indicate that maximal glycolytic rate is significantly
higher in PH-PASMC (Fig. 2C). The glycolysis inhibitor, 2-deoxy-D-
glucose reduced the acidification rate in both control- and PH-
PASMC (Fig. 2A).3.3. The activities of complex I, II and III are reduced in pulmonary
arterial smooth muscle cells isolated from rats with pulmonaryhypertension
To understand the role of mitochondrial respiratory chain
Complexes in mitochondrial dysfunction and glycolytic switch, we
utilized a novel cell permeabilization protocol to allow us to
measure individual Complex activity in cells. Our data indicate
that the activities of both Complex I and Complex II are decreased
by ∼50% in PH-PASMC (Fig. 3). Unfortunately, the Seahorse XF
instrument is limited to 4 injections, so, we could not examine
substrate utilization from all mitochondrial Complexes in a single
experiment. Thus, in a separate set of experiments, we measured
Complex I and Complex III activity. Our data indicate that Complex
III activity is also inhibited by ∼50% in PH-PASMC (Fig. 4). Inter-
estingly, this 50% reduction in Complex I–III activity correlates well
with the ∼50% decrease in overall mitochondrial OCR (Fig. 1).
3.4. Mitochondrial ROS generation and membrane potential are in-
creased in pulmonary arterial smooth muscle cells isolated from rats
with pulmonary hypertension
Our data indicate that PASMC from MCT-treated rats have sig-
nificantly increased mitochondrial ROS production (Fig. 5). This
observation correlates well with our finding of respiratory chain
dysregulation in PH rats, as more electrons can escape between
Complexes and become trapped in oxygen, potentially increasing
superoxide levels in the mitochondria. The mitochondrial mem-
brane potential is also increased in PASMC from MCT-treated rats
(Fig. 6). This result is surprising in the context of reduced activity
of Complexes I–III, all of which maintain membrane potential, in
Fig. 3. Complex I and Complex II dependent respiration is attenuated in pulmonary arterial smooth muscle cells isolated from rats with pulmonary hypertension. The
Seahorse XF24 analyzer was used to take OCR measurements in PASMC (40,000/0.32 cm2) isolated from control (red) and PH (blue) rats to determine Complex I and II
respiratory activity (A). Both Complex I (B) and Complex II (C) activities are attenuated in PH- compared to Control-PASMC. Values are means7SEM. *(po0.05 vs. Control
PH-PASMC, N¼5–15 measurements from 3 independent SMC isolations). (For interpretation of the references to color in this figure legend,the reader is referred to the web
version of this article.)
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3.5. Loss of complex I assembly in pulmonary arterial smooth muscle
cells isolated from rats with pulmonary hypertension
In order to evaluate individual intact Complexes we utilized
native blue gel electrophoresis on isolated fresh mitochondria
from control- and PH-PASMC. Our data indicate that PASMC iso-
lated from PH rats have a marked loss of Complex I (Fig. 7).
However, we found that Complex II remained unchanged and
Complex III was significantly elevated in PH-PASMC. This finding
contradicts with our data demonstrating that Complex II and III
activities are both decreased in PH-PASMC (Figs. 3 and 4). One
possible explanation is that the uncoupling of electron transport
chain due to derangements in Complex I prevents Complex II and
III from transporting electrons effectively. However, the increased
levels of Complex III may explain the increase in mitochondrial
membrane potential we observe in PH-PASMC (Fig. 6).4. Discussion
Our data suggest that the mitochondrial dysfunction in asso-
ciated with PH occurs via a loss of Complex I assembly and
Complex I activity. Our data also suggest that Complex I dysre-
gulation appears to lead to the inhibition of Complexes II and III.
The mitochondrial electron transfer chain consists of five distinct
Complexes [14]. Complex I is the largest enzyme and plays criticalroles both in transferring electrons from reduced NADH to Coen-
zyme Q and in maintaining the proton electrochemical gradient
across the inner mitochondrial membrane [14]. Complex I contains
a large number of different subunits (45) that are all required for
catalytic function and are conserved across different species. The
core of Complex I is assembled by 14 subunits [15]. Seven subunits
are encoded by mitochondrial DNA and seven are encoded by
nuclear DNA [15]. The mitochondrial derived subunits play an
important role in proton pumping from the matrix, whereas the
non-mitochondrial subunits are involved in electron transfer [16].
Electrons flowing from NADH to Coenzyme Q induces proton
translocation across the mitochondrial membrane secondary to
conformational changes in the membrane arm of Complex I [17].
Two electrons pump four protons and this contributes to the
electrochemical gradient that drives further ATP synthesis. The
function of the other 31 subunits is largely unexplored due to
instability and the trans-membrane nature of Complex I. However,
these functions are likely involved in the assembly and stabiliza-
tion of the multimeric Complex, regulation of activity, and pro-
tection against reactive oxygen species. Mutations that affect
Complex I assembly lead to severe childhood diseases. For ex-
ample, fatal infantile lactic acidosis [18] is a fatal Complex I defi-
ciency disorder, linked to mutations in several nuclear-encoded
subunits. This disease is characterized by lactate buildup in the
body due to the inability to process pyruvate via oxidative phos-
phorylation. Leigh syndrome, characterized with respiratory ab-
normalities, nystagmus, ataxia, dystonia and hypotonia, is the
most frequent presentation of Complex I deficiency [19,20], also
Fig. 4. Complex III dependent respiration is attenuated in pulmonary arterial smooth muscle cells isolated from rats with pulmonary hypertension. The Seahorse XF24
analyzer was used to take OCR measurements in PASMC (40,000/0.32 cm2) isolated from control (red) and PH (blue) rats to determine Complex I and III respiratory activity
(A). Both Complex I (B) and Ccomplex III (C) activities are attenuated in PH- compared to Control-PASMC. Values are means7SEM. *(po0.05 vs. Control PH-PASMC, N¼10
measurements from 3 independent SMC isolations). (For interpretation of the references to color in this figure legend,the reader is referred to the web version of this article.)
Fig. 5. Mitochondrial ROS production is increased in pulmonary arterial smooth
muscle cells isolated from rats with pulmonary hypertension. PASMC were pre-
incubated with the mitoSOX red fluorescent dye. Digital images of mitoSOX fluor-
escence were obtained by fluorescent microscopy. Representative digital images
from PASMC isolated from control and PH rats SMC are shown. Quantification of
the fluorescent signal indicates that ROS production is increased in PH-PASMC.
Data are plotted as mean fluorescence intensity (7SEM). *(po0.05, N¼10).
Fig. 6. Mitochondrial membrane potential is increased in pulmonary arterial
smooth muscle cells isolated from rats with pulmonary hypertension. PASMC were
pre-incubated with TMRM to polarized mitochondria. Digital images of TMRM
fluorescence were obtained using fluorescent microscopy. Representative digital
images from PASMC isolated from control and PH rats SMC are shown. Quantifi-
cation of the fluorescent signal indicates that the mitochondrial membrane po-
tential is increased in PH-PASMC. Data are plotted as mean fluorescence intensity
(7SEM). *(po0.05, N¼10).
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Fig. 7. Complex I assembly is attenuated in pulmonary arterial smooth muscle cells isolated from rats with pulmonary hypertension. Mitochondria, obtained from PASMC
isolated from control and PH rats SMC, were subjected to Native Blue electrophoresis to preserve the respiratory Complexes (A). Complex I levels are significantly reduced in
PH-PASMC (B). Complex II and V levels are unchanged and Complex III levels are increased in PH-PASMC. The image shown is representative of three independent SMC
isolations experiments. Data are plotted as mean7SEM, *po0.05.
R. Rafikov et al. / Redox Biology 6 (2015) 278–286284associated with elevated lactate levels fluid [21]. Although any
oxidative phosphorylation Complexes defect can contribute to
Leigh syndrome, Complex I deficiency is the primary cause of the
disease. Mutations in six mitochondrial and eleven nuclear en-
coded Complex I subunits and several assembly factors have been
linked with Leigh syndrome [22].
The inhibition of Complex II and III, likely as result of reduced
Complex I activity, occurred despite the fact that Complex II pro-
tein levels were similar between control and PH PASMC and
Complex III levels were elevated in the PH cells. Thus, changes in
protein levels do not appear to explain the loss of function we
identified in Complex II and III. However, it has been shown that
the majority of Complex I exists within respiratory chain super-
complexes or ‘respirasomes’ that are composed of Complex I,
Complex III, and Complex IV [23]. These supercomplexes appear to
have functional advantages, including increased efficacy of elec-
tron-, proton- and substrate flow, as well as stabilization and
protection from degradation [24,25]. Overall this decreases elec-
tron leak that can lead to the formation of reactive oxygen species
(ROS) as well as proton leak [26]. It has been further suggested
that Complex I assembly is required for supercomplex formation
[27]. Moreover, the requirement for supercomplex formation to
allow efficient electron transport chain function may explain the
dysfunction that has been identified in other complexes associated
with Complex I mutations; for example, Complex III defects have
been identified in some patients with NDUFS4 subunit mutations
[28,29] and Complex IV deficiency [30] has been found in some
patients with defects in the Complex I assembly factor, C20ORF7.17
[31]. Thus, the need for suplercomplex formation may explain why
derangements in Complex I in PH-PASMC lead to dysfunction of
other respiratory chain complexes.
Complex I is also an important site for the generation of ROS
and the electrochemical gradient. Paradoxically, we found that the
loss of Complex I activity was associated with increased ROS
production and increased mitochondrial membrane potential. As
Complex III is another major site of ROS production and proton
exchange, our observed increase in Complex III in PH-PASMC may
compensate for the loss of Complex I and contribute to the in-
crease in both ROS and the mitochondrial potential. While Com-
plexes I and III are thought to generate most of the mitochondrial
ROS [32], heterogeneity in the amount of these Complexes within
the mitochondria also determines their individual importance.
Thus, ROS generation is predominantly from Complex III in hy-
poxic myocytes [33], while Complex II has been shown to be the
predominant source in the hypoxic lung [34]. Further, Complex IIactivity is increased in the right ventricle in the MCT rat model of
PH and is the major ROS generator [35]. However, in PH the role of
mitochondrial derived ROS is controversial with competing stu-
dies suggesting that mitochondrial ROS can either increase or
decrease. Decreased levels of mitochondrial derived ROS have
been found in PASMC isolated from humans with PH [36], the
fawn hooded rat [37], and hypoxia-, and MCT-induced PH [38].
While mitochondrial ROS have been shown to be increased in PH
associated with PPARγ inhibition [39] and in PAEC exposed to ET-1
[11] or ADMA [10]. Although more work is clearly needed to clarify
the role of mitochondrial ROS in the development of PH, it is
reasonable to conclude that the PH field has reached a consensus
that the mitochondria play an important role in the development
of PH.
Our data also confirm previous studies that vascular cells in PH
exhibit an increase in aerobic glycolysis. This glycolytic switch was
first hypothesized in the 1920's by Otto Warburg, as a mechanism
that gives a proliferative advantage to cancer cells [40]. The hy-
poxic microenvironment around tumors appears to stimulate the
metabolic switch to glycolysis [41]. Interestingly, some animal
models of PH utilize hypoxia as an inducer. PH is also character-
ized by the tumor-like growth of vascular wall cells. Therefore, the
metabolic switch in PH may also be induced by hypoxia. Hypoxia
inducible factor (HIF) is known to activate survival genes that are
linked to cellular adaptation to hypoxia [42]. For example, HIF
induces vascular endothelial growth factor (VEGF), hepatocyte
growth factor receptor (c-Met), erythropoietin, transforming
growth factor-α (TGF-α), platelet-derived growth factor-β (PDGF-
β) and glucose transporter GLUT1, and is thus able to influence
many cellular activities, including angiogenesis, glycolysis and cell
survival [43]. HIF also plays a critical role in shifting ATP genera-
tion from oxidative phosphorylation to glycolysis. This appears to
be dependent on mammalian target of rapamycin (mTOR) activa-
tion via Akt signaling [44]. We have recently reported that Akt1
signaling can be enhanced through a single nitration at Y350 [13].
This, in turn, leads to mitochondrial dysfunction secondary to the
mitochondrial redistribution of eNOS followed by the downstream
activation of HIF [11]. As nitration is increased in multiple models
of PH [45–51] it is possible that this type of Akt1 activation [52]
may be shifting the cellular metabolic state by inhibiting mi-
tochondrial respiration and activating glycolysis at the same time.
However, this is a speculation and more work will be required to
unravel the mechanisms by which the glycolytic switch occurs
during the development of PH.
In conclusion, our data suggest that, in PASMC isolated from PH
R. Rafikov et al. / Redox Biology 6 (2015) 278–286 285rats, derangements in Complex I can also reduce the activity of
Complex II and III in the ETC. This appears to have effects on the
activity of downstream respiratory chain complexes as well as
mitochondrial ROS generation and membrane potential. There is
also a compensatory metabolic switch to glycolysis for ATP gen-
eration. Similar to tumor growth, this metabolic reprogramming
likely leads PASMC proliferation and vascular remodeling. We
speculate that therapies targeted at restoring Complex I activity
could have potential in the treatment of PH.Acknowledgments
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